bluebird bio details plans for the commercial launch of Lyfgenia gene therapy for patients ages 12 and older with sickle cell disease and a history of vaso-occlusive events.
bluebird bio, announced the details of its U.S. commercial infrastructure to support timely, equitable access to Lyfgenia (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved gene therapy for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs)